In the March 2024 quarter, the company’s revenue grew by 17.2% year-on-year to Rs1,905 crore. Net profit jumped by 29.4% to Rs438 crore. The management commentary during an analyst call after the results hinted at a sustained demand for rooms in FY25.
UBS sells shares worth Rs 480 crore in Concord Biotech, IIFL Securities, 2 more stocks via block deals
UBS sold holdings in Concord Biotech, Five Star Business Finance, IIFL Securities, and Marksans Pharma through block deals, totaling Rs 480 crore. The largest sale